Tag Archives: social-media

ApexBrasil and ABIQUIFI Deepen Strategic Alliance with Life Science Nation to Globalize Brazil’s Life Science Ecosystem and Leveraging the RESI JPM January Event 

28 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

São Paulo – Boston | October 2025

Brazil is taking a significant step toward global integration in the life sciences. Last week, ApexBrasil (the Brazilian Trade and Investment Promotion Agency) and ABIQUIFI (the Brazilian Association of Pharmaceutical Inputs Industry) hosted Life Science Nation (LSN) and Ganesha Labs in São Paulo for a week of meetings, workshops, and strategic dialogues with key stakeholders from across the national innovation and investment landscape. 

The visit culminated during the Corporate Venture in Brasil 2025 Conference, held in São Paulo and co-hosted by ApexBrasil, which gathered leading investors, corporate venture leaders, development agencies, and innovation stakeholders to strengthen Brazil’s position in the global market. 

At the conference, LSN’s CEO, Dennis Ford, delivered a masterclass on running global fundraising campaigns and building two-way innovation bridges between regional science and global capital. This was followed by a panel discussion, “Where Brazil Is and Where We Should Aim Towards,” featuring KX Ventures, IKJ, Sebrae, Ganesha Labs, and Life Science Nation, and moderated by Marcos Valadares of ABIQUIFI. 

Over several days surrounding the conference, ApexBrasil and ABIQUIFI facilitated a series of high-level introductions that connected LSN and Ganesha Labs with leaders from accelerators, investment groups, and research institutions across Brazil. These discussions focused on aligning Brazil’s growing innovation infrastructure with global commercialization frameworks and investor networks. 

The São Paulo visit capped two years of collaboration between the organizations, during which ApexBrasil and ABIQUIFI have sent multiple cohorts of Brazilian life-science companies to LSN’s Redefining Every Stage of Investment JPM events and LSN Labs training programs. 

Together, they have provided Brazilian entrepreneurs with a structured path to international investors and licensing partners, and a deeper understanding of how to prepare and execute a global fundraising campaign. 

This ongoing collaboration is laying the groundwork for Brazil to become a formal anchor node in the LSN Global Partnering Ecosystem. This worldwide network links regional innovation hubs to global capital and corporate partners. Through continued coordination, the parties aim to establish a lasting two-way innovation bridge between Brazil and LSN’s international ecosystem, enabling Brazilian technologies to access global markets while channeling international investors and strategic partners into the country’s rapidly expanding life-science sector. 

According to Dennis Ford, Founder and CEO of Life Science Nation, 

“Brazil’s scientific depth and entrepreneurial momentum make it one of the most exciting emerging markets in life sciences. ApexBrasil and ABIQUIFI are doing exactly what global investors want to see—creating a coordinated pathway that connects local innovation with international capital and commercialization opportunities. LSN is proud to help Brazil take this next step.” 

Norberto Prestes, CEO of ABIQUIFI, emphasized the export and funding side of the bridge: 

“Brazil has a rich foundation of science and talent. Our goal is to help these innovations secure the visibility, funding, and partnerships they need to reach international markets. The collaboration with LSN provides the structure and access needed to make that happen.” 

Debora Lima of ApexBrasil highlighted the importance of bringing international investors into the Brazilian ecosystem: 

“Our mission is to connect Brazil with the world—to bring investors, partners, and collaborators to see firsthand the innovation emerging here. Working with LSN allows us to open new channels for global capital to engage directly with Brazilian startups and research institutions.” 

About Life Science Nation

Life Science Nation (LSN) is a global matching and partnering engine that connects early-stage life-science companies with investors and licensing partners through its integrated ecosystem—including the LSN Investor & Licensing Partner Database, the RESI Conference Series, and LSN Labs Accelerator. LSN has supported more than 400 companies in raising over $5 billion in verified funding worldwide.

About ApexBrasil

ApexBrasil promotes Brazilian products and services abroad and attracts foreign investment to strategic sectors of the Brazilian economy, strengthening national competitiveness and international presence.

About ABIQUIFI

ABIQUIFI represents the Brazilian Pharmaceutical Inputs Industry, advancing innovation, quality, and competitiveness across the national health and life-sciences sector.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

LSN Ecosystem Deal Matrix $1.29 Billion and Counting 

15 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Across Life Science Nation (LSN)’s interconnected network, from the Investor & Licensing Partner Database and RESI Conference Series to LSN Labs, 90 companies have publicly disclosed raising capital or signing licensing deals sourced directly through LSN.  LSN has been collecting this disclosed data and, after reaching 90 deals, wanted to extrapolate the compelling metrics behind the LSN engine that facilitated the deals, known as the LSN Ecosystem.

Together, they’ve secured $1.29 billion in verified funding. When factoring in the broader global community of 9,000+ startups that have engaged with LSN tools and programs and gone through the RESI turnstiles, the estimated impact reaches $6.4 billion. This isn’t modeled data; these are real companies, real partners, and real outcomes. It’s proof that structured global partnering delivers measurable success.

A Marketplace That Works — and Scales

At first glance, the dataset lists 90 companies and 52 investors. On closer inspection, that ratio reflects how healthy marketplaces behave. Each transaction represents multiple funding relationships, roughly 100 to 150 discrete deals in total, many of which are undisclosed but very much real.

  • For startups, closing $1.29 billion through LSN-facilitated partnerships signals one of the strongest verified conversion rates in early-stage life sciences.
  • For investors, repeat participation by six global funds, including corporate venture, pharma, and family offices, demonstrates a growing cycle of trust and sourcing efficiency within LSN’s ecosystem.

This is not a collection of introductions; it’s a living marketplace where structure, data, and discipline transform intro meetings into ongoing dialogue, building relationships that ultimately lead to transactions.

Where the Money Moves: The Four Domains (4Ds)

SECTOR DISCLOSED FUNDING ($) % SHARE COMMENT
Drugs (Therapeutics) 1,106,490,000 83% Core growth engine for global biotech
Devices (Medtech) 120,820,000 9% Strategic investments and exits rising
Diagnostics & Tools 111,330,000 8% A precision frontier gaining traction
Digital Health Emerging (<1%) — Expanding rapidly as AI matures and the software moves adroitly

Therapeutics dominate the dollars, but the deal flow is distributed, indicating a balanced and resilient early-stage market that spans drugs, devices, diagnostics, and digital health alike.

Even Distribution, Uneven Costs

It’s no surprise that therapeutics absorb most of the capital; drug development is costly and front-loaded. A single preclinical or IND-enabling round can match the combined raises of multiple device or diagnostics startups. But when you look at deal volume, not just deal size, the picture changes. The 90 funded companies are evenly distributed across the 4Ds:

SECTOR  COMPANIES FUNDED  SHARE OF TOTAL 
Drugs (Therapeutics)  31 34%
Diagnostics & Tools  26 29%
Devices (Medtech)  23 26%
Digital Health  10 11%

The big money may flow into drugs, but the deals are happening across all four domains. That balance defines a healthy market, diversified, dynamic, and alive.

Average Deal Size Across the 4Ds

SECTOR  AVERAGE RAISE PER COMPANY ($)  INSIGHT 
Drugs (Therapeutics)  $35.7 million Reflects the high capital intensity of preclinical and early clinical development
Devices (Medtech)  $5.3 million Medtech investors focus on de-risked prototypes and regulatory progress
Diagnostics & Tools  $4.3 million Enabling and precision technologies attract steady, mid-range funding
Digital Health  >$3 million Early but fast-growing; deal sizes expected to rise with data maturity

These numbers capture a simple truth: Drug rounds dominate in size, but early-stage innovation thrives across every domain. The LSN ecosystem delivers results across all four, not just where the biggest checks are written.

The Signal: Efficiency Is the New Advantage

As global capital tightens, efficiency wins. With RESI London (Dec 2025) and RESI JPM (Jan 2026) approaching, startups and investors alike are leaning into systems that don’t just connect, they convert. LSN’s rhythm of data, readiness, and disciplined outreach has become the commercialization backbone for early-stage life sciences worldwide.  “At RESI, we don’t chase headlines; we measure outcomes. The companies and investors in this dataset are the proof.”

Join the Momentum. Be Part of the Data.

The next cycle begins now. Don’t miss your chance to access the world’s most effective life science partnering platform.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

Life Science Nation and The Ganesha Lab Launch a Global Two-Way Innovation Bridge Connecting South America, Anchored in São Paulo, Brazil, to the International Healthcare Arena 

23 Sep

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022São Paulo, Brazil – September 23, 2025 – In a landmark move to expand Latin America’s role in the global life sciences sector, Life Science Nation (LSN) and The Ganesha Lab (TGL), Latin America’s premier life sciences scale-up platform, announce a strategic alliance to launch a dedicated bricks-and-mortar accelerator hub in São Paulo by the end of 2025.

Uniting Global Scale with Local Depth

The São Paulo-based facility will serve as the Latin American anchor node of LSN’s global partnering backbone, a system of affiliated tech hubs, economic development agencies, incubators, and accelerators worldwide, all connected through LSN’s two-way innovation bridge model.

This new effort builds upon years of development work with leading Brazilian stakeholders, including Abiquifi and ApexBrasil, alongside local governments, universities, and innovation agencies, as well as service providers, to ensure the hub will be fully integrated into Brazil’s national strategy for life sciences by both LSN and TGL.

  • The Ganesha Lab brings regional depth: through its BigInBIO scale-up platform, TGL sources and mentors startups, delivers structured readiness programs, builds an alumni base across Latin America, and maintains strong relationships with CROs, universities, governments, and pharma partners. As LSN’s anchor partner for Latin America, TGL provides the credibility and local integration that enable the bridge to function.
  • Life Science Nation brings global reach: as the architect of the two-way innovation bridge, LSN provides a commercialization-first partnering backbone that includes its curated 4,000-profile investor and licensing partner database, AI-driven readiness assessments, BD Assist outbound campaign execution, and the five annual RESI investor conferences worldwide, where more than 400 companies have raised over $5B.

Tangible, Two-Way Impact

  • Outbound: Building on TGL’s BigInBIO platform, Latin American startups will be mentored and readied regionally, then advanced into LSN Labs’ commercialization-first global roadshow process, narrative refinement, global target list creation, CRM-driven outreach, and full integration into international RESI conferences.
  • Inbound: Global life sciences technologies, investors, and licensing partners will be brought into Brazil through LSN’s ecosystem, leveraging TGL’s local networks to accelerate collaboration, validation, and market entry.
  • Capital & Partnering Alliances: International investors and licensing partners from LSN’s global network will syndicate with Brazilian VCs, corporates, and pharma, expanding capital access and helping local partners build a global footprint.

Together, TGL and LSN create a seamless pathway: from regional readiness → to global campaign execution → to inbound technologies and capital integrating into Latin America. The São Paulo accelerator will serve as the anchor node for Latin America in LSN’s global partnering backbone.

Accelerator Operations and Ecosystem Collaborations

A newly formed Brazilian team will operate the São Paulo accelerator, working with new and existing partners from local government, top universities, regional innovation agencies, and service providers. The accelerator will act as a permanent node, building local capacity while embedding Latin America into the global life sciences economy.

“We are committed to powering innovation in both directions, helping Latin American startups scale globally and enabling global innovators to leverage Brazil’s unique advantages,” said Dennis Ford, Founder & CEO of Life Science Nation.

“Together, we are creating an innovation bridge that not only builds businesses but also strengthens Brazil’s role as the leading gateway for life sciences innovation in Latin America,” said Markus Schreyer, Founder & CEO of The Ganesha Lab.

“LSN has built a precision matching and meeting connection engine for over a decade, helping more than 400 companies raise $5B. Anchoring the accelerator in Brazil will strengthen the LATAM market and connect the region directly into LSN’s global backbone. The time is right to bring Latin America into the network and expand its global life science footprint,”  said Matt Stanton, LSN’s VP of LATAM Business Development.

The program is targeting going live by the end of 2025 or early 2026. The São Paulo hub will be the first of its kind in Latin America, with the potential to replicate across other innovation centers in the region, further embedding Latin America into the global life sciences economy.

The partnership will also be highlighted at the upcoming BioHunt Summit 2025 in Miami, where Dennis Ford and Markus Schreyer will hold a fireside chat to expand on the announcement.

About Life Science Nation (LSN)

Life Science Nation (LSN), founded by Dennis Ford, is a global leader in connecting early-stage life science companies with capital investors and licensing partners. LSN owns and operates the LSN Investor & Licensing Partner Database (4,000 curated profiles), the Redefining Early-Stage Investments (RESI) Conference Series (five global partnering events annually), and the LSN Newsletter (60,000 global readers), alongside podcasts and published works such as The Life Science Executive’s Fundraising Manifesto.

Through its accelerator arm, LSN Labs, LSN has pioneered the two-way innovation bridge model, a partnering backbone that affiliates with tech hubs, incubators, accelerators, and economic development agencies worldwide. This model enables regions, patient groups, and nonprofits to aggregate technology assets, launch them outbound into global markets, and simultaneously bring inbound capital, licensing partners, and technologies into their ecosystems. Over the past decade, LSN has helped more than 400 companies raise over $5 billion through global roadshow campaigns and partnering events.

About The Ganesha Lab (TGL)

The Ganesha Lab (TGL), founded by Markus Schreyer, is Latin America’s premier life sciences scale-up platform. Through its flagship program BigInBIO, TGL provides structured readiness programs, mentoring, and founder development for biotech and health startups. Selected companies may also receive investment support, with TGL maintaining long-term engagement for three years or more post-program through its alumni network.

With strong ties to CROs, universities, governments, and pharma across the region, TGL plays a vital role in sourcing and nurturing the most promising science-based ventures in Latin America, preparing them for international scale-up and investment. TGL’s proven regional expertise and credibility make it the ideal anchor partner for launching the São Paulo accelerator and establishing Latin America as a key node in the global life sciences economy.

Tags: , , , , , , , , , ,